Shanghai Fosun Pharmaceutical (Group) Company Limited operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Shanghai Fosun Pharmaceutical (Group) Company Limited with three other
companies in this sector in China:
Guangzhou Baiyunshan Pharmceutical Holdings Co Ltd
sales of 20.95 billion Chinese Renmimbi [US$3.10 billion]
of which 41%
Tasly Pharmaceutical Group Company Limited
(16.09 billion Chinese Renmimbi [US$2.38 billion]
of which 57%
was Medicine Commerce), and
Humanwell Healthcare Group Co Ltd
(15.45 billion Chinese Renmimbi [US$2.28 billion]
of which 99%
was Medication & Health Products).
During the year ended December of 2017, sales at
Shanghai Fosun Pharmaceutical (Group) Company Limited were 18.36 billion Chinese Renmimbi (US$2.71 billion).
increase of 26.6%
versus 2016, when the company's sales were 14.51 billion Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Shanghai Fosun Pharmaceutical (Group) Company Limited
(and since 2012, sales have increased a total of 152%).
Sales of Pharmaceutical Manufacturing and R&d saw an increase
28.5% in 2017, from
10.15 billion Chinese Renmimbi to 13.04 billion Chinese Renmimbi.